WASHINGTON — There’s an unlikely kumbaya in Washington this year: both President Trump and House Speaker Nancy Pelosi have made it clear that lowering the cost of prescription drugs is among their top priorities.
But with a fiercely resistant pharmaceutical lobby, an unpredictable White House, and split control of Congress, can 2019 be the year something finally gets done?
STAT’s Washington correspondents Lev Facher and Nicholas Florko explore these questions and fielded more on this hot-button issue.
Download slides here (PDF). You may view the webinar recording below.